Functional Target Validation for Alzheimer's Disease-Related Dementias
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute of Neurological Disorders and Stroke (NINDS) seeks to support innovative research projects aimed at the comprehensive functional validation of newly identified therapeutic targets for Alzheimer’s Disease–Related Dementias (ADRD). This initiative addresses a critical challenge in developing effective treatments for ADRD and other complex central nervous system disorders—the lack of well-validated targets linked to disease mechanisms. By rigorously establishing causal relationships between target modulation and relevant physiological outcomes, the program aims to enhance confidence in potential therapeutic strategies, thus accelerating translational research and de-risking subsequent development efforts. The initiative is planned to be funded through a phased award mechanism, such as an R61/R33 grant. The first phase involves the development of tailored technologies, models, and protocols to modulate candidate targets and evaluate their effects in relevant in vitro and in vivo disease models. Upon meeting milestone-based criteria for technical feasibility and proof of concept, projects can proceed to a second phase focused on validating target effects across multiple experimental systems and collaborating laboratories, following NIH standards for rigor and reproducibility. Although applications are not currently being solicited, this notice serves to give potential applicants ample time to prepare projects and establish necessary cross-disciplinary partnerships.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute of Neurological Disorders and Stroke (NINDS) is interested in supporting ambitious research projects that propose comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer’s Disease–Related Dementias (ADRD). A major barrier to the development of effective treatments for ADRD, as well as other complex central nervous system disorders, is the lack of well-validated targets that are clearly linked to disease mechanisms. Successful translation of basic discoveries into the clinic depends on the rigor of target validation and confidence in a causal relationship between modulation of a target and its functional physiological consequences relevant to treating or preventing disease. This initiative aims to de-risk subsequent translational research and accelerate the development of novel therapeutic strategies.
NINDS believes that this initiative would be most appropriately supported by a phased award mechanism (for example, R61/R33). In the initial phase, support would be provided for the development of customized technologies, models, and protocols to modulate the expression or activity of candidate targets and to assess their physiological consequences in relevant in vitro and in vivo disease models. Upon successful achievement of predefined, milestone-based technical feasibility and proof-of-concept criteria, projects would transition to the second phase focused on measuring and cross-validating the effects of target modulation across multiple experimental modalities and collaborating laboratories, in accordance with NIH rigor and reproducibility guidelines.
Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop responsive projects and establish appropriate cross-disciplinary collaborations.
